CDK4 and breast carcinoma: Clinically, dinaciclib has displayed significant toxicity in a phase I trial (23), while the FDA-approved CDK4/6 selective inhibitor abemaciclib has shown remarkable efficacy in safely treating ER+/HER2–/RB1WT breast cancer (24, 25).